Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results $96.0 million in 2Q VYJUVEK revenue and$525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH, August 4, 2025 (GLOBE NEWSWIRE) – Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business ...